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Breast cancer is the most common cancer and the second most
frequent cause of cancer death among women in modern society
(Parker et al, 1997). Among all factors, vascular endothelial
growth factor (VEGF) is recognized to play a predominant role in
breast cancer prognosis (Ref et al, 1997), especially in node-nega-
tive breast cancer (Gasparini et al, 1997). VEGF is a glycosylated,
multifunctional cytokine that is abundantly expressed and secreted
by most human and animal tumours examined thus far (Dvorak et
al, 1995). To date, in vivo as well as in vitro experimental studies
have demonstrated that VEGF exerts a number of important
biological actions on endothelial cells:
1. It acts with a potency some 50 000 times that of histamine to
increase the permeability of microvessels to circulating
macromolecules (Senger et al, 1983), and this activity is likely
to account for the well-documented hyperpermeability of
tumour blood vessels (Senger et al, 1993)
2. It is a selective endothelial cell mitogen (Ferrara et al, 1991).
VEGF activity is mediated by two high affinity receptors with
ligand-stimulated tyrosine kinase activity: VEGFR-1/flt-1 and
VEGFR-2/flk-1 (Hanahan, 1997). Targeted homozygous null
mutations of VEGFR-1/flt-1 are essential for endothelial organiza-
tion during vascular development, while VEGFR-2/flk-1 is
required for the formation of blood islands and also for
haematopoiesis (Millauer et al, 1993). The expression of these
receptors occurs mainly in vascular endothelial cells. This leads
most studies to focus on one aspect of the roles of VEGF,
i.e. angiogenesis, as a paracrine growth factor for endothelial cells.
It is now well recognized that the expression of VEGF is closely
related to poor prognosis in breast cancer, despite the fact that the
relationship between angiogenesis and poor prognosis remains
equivocal (Martin et al, 1997). A number of explanations have
been employed for these discrepancies, although none of them are
conclusive (Fox and Harris, 1997). In this connection, we hypoth-
esize that VEGF may have other regulatory roles during the
development and progression of breast cancer apart from angio-
genesis.
More recently, the expression of VEGF receptors has been
detected in several types of non-endothelial cells, such as
melanoma cell lines (Gitay-Goren et al, 1993), some leukaemic
cell lines (Shibuya et al, 1995), NIH 3T3 cells, HeLa cells, Balb/c
3T3 cells (Enomoto et al, 1994), and retinal progenitor cells (Yang
and Cepko, 1996), suggesting that VEGF receptors are not
restricted to endothelial cells. Moreover, Mascood et al (1997)
have reported that in AIDS-associated Kaposi’s sarcoma the
tumour cells express not only high levels of VEGF but also its
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Correspondence to: YC Wongreceptors. These studies strongly suggest that VEGF may act as an
autocrine growth factor both in in vitro and in vivo conditions. To
date, however, no study has been made to ascertain whether VEGF
also play an autocrine growth regulatory role in adenocarcinoma.
We have established a new animal model for breast cancer,
using a combination of 17b-oestradiol and testosterone as
‘carcinogens’ (Wong et al, 1999; Xie et al, 1999a, 1999b). In this
report, taking advantage of the animal model, we have demon-
strated that both the VEGF and its receptors (flt-1 and flk-1) are
overexpressed in this hormone-induced mammary cancer. Based
on these observations, we conclude that in mammary cancer,
VEGF can regulate, in addition to endothelial proliferation and
angiogenesis, also growth of tumour cells by an autocrine mecha-
nism mediated through its receptors.
MATERIALS AND METHODS
Animals and treatment
All animals used in this study were 3-month-old, sexually mature
Noble rats weighing 180–210 g at the beginning of the experi-
ment. These rats were surgically implanted subcutaneously (s.c.)
in the inguinal region, under pentobarbitone anaesthesia, with four
2.0-cm long Silastic tubings (inner diameter 1.6 mm, outer
diameter 3.2 mm) containing testosterone propionate (T) and one
1.0-cm long Silastic tubing containing 17b-oestradiol (E2). The
rats were palpated regularly for mammary tumours starting from
2 months after treatment. The rats were killed when moribund or
when a tumour > 2 cm in diameter were detected. All rats used
were bred in the Department and had tap water and diet available
ad libitum at all times.
Histopathological examination
The mammary tumours were fixed immediately after removal in
10% formalin buffered with 0.1 M phosphate buffer (pH 7.2),
trimmed and embedded in paraffin. Paraffin sections (4-mm in
thickness) were prepared and stained with haematoxylin and eosin
(H&E) for histopathological examination, using the criteria and
classification of mammary tumours as outlined by Russo et al
(1990).
Single-labelling immunohistochemistry
Immunohistochemical staining for VEGF was performed on
formalin-fixed paraffin sections, using an avidin–biotin
immunoperoxidase technique. A rabbit polyclonal and a goat
polyclonal antibodies for rat VEGF (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) were used at a 1:50 and 1:100 dilutions
respectively. The sections were dewaxed in xylene and rehydrated
through graded alcohol before being incubated for 20 min in 0.3%
hydrogen peroxide (v/v) in methanol to inhibit endogenous per-
oxidase. The antibody binding epitope of the antigen was retrieved
by microwave treatment for 10 min in boiling 10 mM citrate buffer
(pH 6.0). The slides were allowed to cool for 20 min in the citrate
buffer before further treatment. After a quick rinse in distilled
water and in phosphate-buffered saline (PBS), the sections were
treated with blocking solution from EliteABC-kit (Vector,
Peterborough, UK) for 20 min. After blotting off the blocking
solution, the sections were covered with primary antiserum against
VEGF and incubated for 1 h at 37°C in a humid chamber. The
sections were then incubated with the appropriate biotinylated
secondary antibody at 1:100 dilution followed by peroxidase-
conjugated avidin–biotin complexes according to the manufac-
turer’s instructions (EliteABC-kit, Vector, Peterborough, UK, and
diaminobenzidine (DAB). The sections were then counterstained
with Meyer’s haematoxylin.
Immunocytochemical staining with rabbit polyclonal antibody
to flt-1 and flk-1 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) was performed in the same way as that of VEGF, except that
microwave treatment was omitted. The dilutions of antibodies for
flt-1 and flk-1 were 1:100 and 1:50 respectively.
Double-labelling immunocytochemistry
To determine the relationship between cell proliferation and
expression of VEGF, flt-1, or flk-1, double immunocytochemical
studies for both Ki-67 and VEGF, flt-1, or flk-1 were performed.
Immunocytochemical staining for VEGF, flt-1 and flk-1 was
performed as described above. The sections were then treated for
10 min in boiling 10 mM citrate buffer (pH 6.0) in a microwave
oven to block antibody cross-reactivity and to retrieve antigens. A
mouse monoclonal antibody against Ki-67 (Novocastra,
Newcastle upon Tyne, UK) was used at 1:500 dilution. The
sections were incubated with the appropriate biotinylated
secondary antibody (1:100) followed by alkaline phosphatase
conjugated avidin–biotin complexes according to the manufac-
turer’s instructions (ABC-AP kit, Vector, Peterborough, UK).
Ki-67 reactivity was recognized as diffuse or dot-like red nuclear.
Controls for immunocytochemistry
The specificity of the reactivity of each antibody was checked by
the following controls: (a) normal adult rat brain as a negative
control for all antibodies (Plate et al, 1993, 1994); (b) fetal rat
kidney sections were used as positive control for antibody against
VEGF, flt-1 and flk-1 (Shim et al, 1996); (c) fetal rat kidney and
skin serving as positive controls for antibody against Ki-67; (d)
preabsorption of the antisera against VEGF, flt-1 and flk-1 with
50-fold concentration of VEGF peptide, flt-1 peptide and flk-1
peptide respectively; (e) preabsorption of antisera with non-
specific antigens such as epidermal growth factor (EGF) and basic
fibroblast growth factor (bFGF); (f) replacement of specific
primary antibodies with the corresponding normal serum.
Evaluation of immunoreactivities of VEGF and its
receptors and Ki-67 labelling index
The intensity of immunostaining for VEGF, flt-1 and flk-1 was
scored as weak and strong. The Ki-67-positive cells were evalu-
ated by ten high-power fields selected according to the intensities
of immunoreactivity for VEGF, flt-1 and flk-1, in six specimens.
Results were given as mean and standard deviation (s.d.). The
Kruskal–Wallis test was applied to correlate the Ki-67 labelling
index (LI) to the intensity of staining for VEGF, flt-1 and flk-1
(Dellas et al, 1996). A value of P < 0.05 was considered to be
statistically significant.
Western blot analysis
Protein extracts were prepared by homogenizing thawed tissue
in a modified radioimmunoprecipitation buffer (50 mM Tris–HCl,
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deoxycholate, 0.1% sodium dodecyl sulphate (SDS)) containing a
cocktail of protease and phosphatase inhibitors (2 mM phenyl-
methylsulphonyl fluoride, 10 mg ml–1 each of aprotinin, leupeptin
and pepstatin A, 1 mM Na3VO4, 50 mM NaF, 5 mM sodium
pyrophosphate), using a tissue tearor (Biospec Products, Inc.). The
tissue lysate was centrifuged at 14 000 rpm for 30 min at 4°C. The
supernatant was collected and its protein content was measured
using DC protein assay (Bio-Rad, Hercules, CA, USA). Equal
amounts of protein (100 mg) were separated by SDS polyacrl-
amide gel electrophoresis (SDS-PAGE). The electrofractionated
proteins were transferred to polyvinyldifluoride (PVDF)
membranes (Bio-Rad, Hercules, CA, USA). Blocking and
washing steps were performed according to the ECL instruction
manual (Amersham Pharmacia Biotech UK Ltd,
Buckinghamshire, UK). The blots were probed for 1–2 h with
primary antibodies (anti-flt-1 or anti-flk-1 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA)), which were the same
as those used in the immunohistochemistry, followed by incuba-
tion with anti-rabbit IgG conjugated to horseradish peroxidase
(Amersham Pharmacia Biotech UK Ltd, Buckinghamshire, UK).
The immunoreactive signals were detected by ECL Western blot
detection reagents (Amersham Pharmacia Biotech UK Ltd,
Buckinghamshire, UK) following the manufacturer’s instructions.
For controls, the antibodies were preincubated with ten fold excess
(by weight) of specific corresponding blocking peptides (flt-1 or
flk-1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA)) for
2 h at room temperature. This competition procedure was used to
validate the specificity of each antibody reagent used for
immunoblots.
RESULTS
Hormone-induced mammary cancer
Mammary carcinoma can be induced readily by the combination
of testosterone and oestradiol protocols as outlined. Fully devel-
oped mammary cancers can be consistently induced between 4 and
6 months. Most tumours observed here were ductal carcinoma
of moderately differentiated to poorly differentiated type. The
detailed histopathology of this induced cancer is described else-
where (Wong et al, 1999; Xie et al, 1999a, 1999b, 1999c). Many
glands had tumour cells completely filling the lumen of mammary
ducts (carcinoma in situ, Figure 1), while others had obviously
broken out from the ductal structure and invaded the stromal
tissues (invasive carcinoma, Figure 2). Isolated clumps or trabec-
ulae of tumour cells were observed frequently interspersed by
stromal connective tissue which was often infiltrated with lympho-
cytic cells. The cancer cells were typically pleomorphic with
highly variable nuclear size and chromatin density.
Expression of VEGF
The expression of VEGF in mammary ductal carcinoma in situ
(Figure 3) as well as in invasive mammary cancer (Figure 4) were
examined. Most tumour cells were moderately or strongly stained
by the anti-VEGF antibody, suggesting the presence of VEGF
protein in these cells. Adjacent, morphologically ‘normal’ ductal
structures were negative to VEGF (Figure 3). On the other hand,
tumour cells that had invaded the stromal connective tissue (Figure
4) were more strongly stained by the antibody than those in
mammary cancer in situ. In control specimens all of them reacted
negatively to normal serum and the antibody preabsorbed with
VEGF peptide, indicating that the staining was specific for VEGF
(Figure 9).
Expression of VEGF receptors
The results showed that both flk-1 and flt-1 were present, in addi-
tion to endothelium, in cancer cells (Figures 5, 6, 7, 8). Closer
examination showed that there was a difference in distribution
between the two receptors, flk-1 and flt-1. The former was present
generally in most cancer cells irrespective of whether they were in
situ or invasive (Figures 5, 6). However, for flt-1, the invasive
tumour was much more strongly expressed than the in situ form of
cancers (Figures 7, 8). Interestingly, in one duct (Figure 5, arrow-
head), in which part of it was occupied by malignant cells while
the remaining was lined by normal cells, the malignant cells all
expressed flk-1, but not the normal cells. Both flt-1 and flk-1 were
negative in adjacent normal ductal epithelial cells (Figures 5, 7).
Preincubation with flk-1 peptide yielded a negative result
(Figure 10).
Correlation between expression of VEGF and Ki-67
index
In order to establish the relationship between VEGF and Ki-67
index, a double-labelling immunocytochemical method was
employed. The results showed that the intensity of VEGF staining
was heterogeneous within the cancer tissue. In an attempt to under-
stand better the significance of heterogeneity in VEGF expression
within the tumour, we assessed the reactivities of this factor
against Ki-67 signal. Of the 1000 cells examined in the area of
strong VEGF reactivity, 58.3% of cells were also Ki-67-positive.
This was much higher than in the weak VEGF reactive area
(P < 0.001; Table 1). This means that the reactivity of VEGF in
tumour cells appeared to be positively correlated with the Ki-67
overexpression. A good example is shown in Figures 11 and 12,
where a large number of Ki-67-positive cells are seen in strong
VEGF reactive zone. By contrast, the weak VEGF reactive zone in
the mammary carcinoma has a lower Ki-67 index. Taken together,
these results indicated that the expression of VEGF is closely
correlated to the proliferation of mammary cancer cells.
Correlation between expression of VEGF receptors and
Ki-67 index
To determine which receptor, flt-1 or flk-1 or both, mediated
proliferation signals, we further examined the correlation between
expression of VEGF receptors and Ki-67 index. Based on the
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Table 1 Correlation between expression of VEGF and its receptors and
Ki-67 index
Ki-67 index %
(mean ± s.e.m.)
Weak Strong P-value
VEGF expression 3.7 ± 0.9 58.3 ± 8.6 <0.001
Flk-1 expression 3.1 ± 1.1 53.9 ± 9.2 <0.001
Flt-1 expression 34.6 ± 9.1 18.4 ± 2.7 <0.0011338 B Xie et al
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Figure 1 Mammary cancer in situ. The tumour cells completely fill the lumen of mammary ducts. An intraductal carcinoma (arrow), illustrating possibly the
evolution of malignancy from a dysplastic site. 150´. Figure 2 Invasive mammary cancer. The tumour cells have obviously broken out from the ductal
structural confine and invaded the stromal tissues. Isolated clumps or trabeculae of tumour cells are seen interspersed within the stromal connective tissue
which is often infiltrated with lymphocytic cells. 150´. Figures 3 and 4 Expression of VEGF in mammary cancer in situ (Figure 3) and in invasive mammary
cancer (Figure 4). Most tumour cells are moderately or strongly stained by the anti-VEGF antibody. The invasive tumour cells are more strongly stained by this
antibody. Note that the adjacent morphologically normal ductal structures are negative to VEGF (arrows). This indicates that VEGF overexpression occurs in
tumour cells only. 150´. Figures 5 and 6 Expression of flk-1 in mammary cancer in situ (Figure 5) and in invasive mammary cancer (Figure 6). The flk-1
reactivity is seen not only in endothelial cells (arrows) but also generally in most tumour cells, irrespective of whether they are in situ or invasive. The ductal
cells, indicated by an arrowhead are positive, despite the general negativity of the duct. 150´. Figures 7 and 8 Expression of flt-1 in mammary cancer in situ
(Figure 7) and in invasive mammary cancer (Figure 8). The flt-1-positive staining cells are seen scattered in mammary cancer. The intensity of flt-1 staining is
more strongly expressed in invasive than in situ mammary cancer. Note negative reaction in normal ducts in Figure 7 (arrows). 150´. Legends are based on
original colour micrographs submitted for review.Co-expression of VEGF and its receptors in mammary cancer 1339
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Figure 9 Negative control, showing no VEGF positive reactivity in the sample preincubated with VEGF peptide. 150´. Figure 10 Negative control, showing
no flk-1 immunoreactivity in the samples preincubated with flk-1 peptide. 180´. Figures 11 and 12 The distribution of VEGF and proliferating cells in
mammary cancer. VEGF and Ki-67 proliferating-associated antigen as visualized by double-labelling immunostaining. Nuclei containing Ki-67 antigen appear
red, whereas cytoplasm containing VEGF appear brown. The strong (S) and weak (W) areas of VEGF reactivities are most obvious at this low magnification as
illustrated in Figure 11. Figure 12 is a higher magnification of a VEGF site with Ki-67-positive cells. Note the positive correlation of Ki-67 to reactivity of VEGF.
60´ (Figure 11), 320´ (Figure 12). Figures 13 and 14 The distribution of flk-1 and proliferating cells in mammary cancer. Flk-1 and Ki-67 proliferating-
associated antigen as visualized by double-labelling immunostaining. Nuclei containing Ki-67 antigen appear red, whereas flk-1 positive cells appear brown in
colour. The strong (s) flk-1 site as illustrated in (Figure 13) is shown at higher power in Figure 14. Note the positive correlation of Ki-67 to flk-1
immunoreactivity. 60´ Figure 13, 320´ (Figure 14). Figures 15 and 16 The distribution of flt-1 and proliferating cells in mammary cancer in situ (Figure 15)
and invasive mammary cancer (Figure 16). The correlation between flt-1 positivity and Ki-67 is not easily apparent. The Ki-67-positive cells appear to scatter
more randomly within the tumour. However, morphometric measurement shows that flt-1 activity is inversely related to Ki-67 activity; i.e. a lower flt-1 is
correlated with higher Ki-67 reactivity. 150´. Legends are based on original colour micrographs submitted for review.reactivities of the tumour to antiserum for flk-1, a similar pattern
of strong and weak receptor reactive zones were established.
When these sections were treated with Ki-67 antiserum, most of
the Ki-67-positive cells were found to be located in the strong
receptor reactive zone. Ki-67 indices were found to be 53.9% and
3.1% in the strong and weak reactive zones for flk-1 respectively
(Table 1; Figures 13 and 14). On the other hand, the flt-1-positive
cells were often scattered within cancer tissues. Of the 1000 cells
examined from strong reactive area, 18.5% expressed immunode-
tectable Ki-67. By contrast, the Ki-67 index for low flt-1 reactive
areas was 34.6%. Figures 15 and 16 show the non-segregation
pattern between proliferating cells (Ki-67-positive cells) and those
expressing flt-1 in mammary cancer in situ (Figure 15) and inva-
sive mammary cancer (Figure 16). These results suggested that,
unlike flk-1, flt-1 reactivity of tumour cells appeared to be
inversely correlated to proliferation marker of this tumour. These
results suggested that flk-1 rather than flt-1 was responsible for
VEGF autocrine proliferative regulation in mammary cancer. It
was also noted that the invasive tumour, though having a high flt-1
reactivity, had a lower Ki-67 index.
Western blot analysis
Immunoblots of tissue extracts from samples of mammary tumour
(lanes 2–4 in Figure 17A) when probed with the rabbit anti flk-1
antibody revealed a strong single band of approximately 170–
175 kDa that was only weakly expressed in the normal mammary
glands (lane 1 in Figure 17A). Preincubation of the anti-flk-1 anti-
body with the corresponding flk-1 peptide abolished the 170–
175 kDa band (lane 5 in Figure 17A), demonstrating the speci-
ficity of this antibody. On the other hand, a distant band with an
apparent molecular mass of 165–170 kDa was observed in
immunoblots of extracts of mammary tumours (lanes 2–4 in
Figure 17B) when probed with the rabbit anti-flt-1 antibody.
However, the 165– 170 kDa band exhibited variable levels of
expression among different tumour samples. In normal mammary
glands, the expression of this band was consistently low (lane 1 in
Figure 17B). Preblot incubation of the flt-1 peptide with the anti-
body results in significant reduction in the 165–170 kDa band
(lane 5 in Figure 17B), showing the specificity of this immunoblot
analysis.
The flk-1 band (~ 170–175 kDa) and the flt-1 band (~ 165–
170 kDa) recognized in our immunoblot studies shows a very
close agreement with molecular masses reported for the rat flk-1
(about 180 kDa) and rat flt-1 (about 180 kDa) (Yamane et al,
1994). In retina, Yang and Cepko (1996) observed that chick flk-1
protein showed a slightly higher molecular weight (~200 kDa)
than murine flk-1 protein (~180 kDa). Takahashi and Shibuya
(1997) observed that an immature form of human flk-1 with a
molecular mass of about 150 kDa could be glycosylated to create a
200 kDa intermediate, and after further glycosylation a mature 230
kDa was expressed on the cell surface. Thus, the minor difference
in molecular weights we observed may be attributed to the differ-
ence of animal species and/or the differential status in post-transla-
tional glycosylations (Seetharam et al, 1995). Our immunoblot
studies showed that both flk-1 and flt-1 are overexpressed in
mammary tumours but the level of expression of flt-1 is variable
among different tumour cases, and confirmed the specificity of the
anti-flk-1 and the anti-flt-1 antibodies used in our immunohisto-
chemistry.
DISCUSSION
We have demonstrated that, in an animal model developed in our
laboratory, the co-expression of VEGF and its receptors, flt-1 and
flk-1, in mammary cancer cells in vivo. Not only have we found
that mammary tumour cells expressed high levels of VEGF, which
is consistent with previous observations (Hendrix et al, 1997), but
also, surprisingly, the expression of its receptors, flt-1 and flk-1, in
mammary cancer cells. Intense reactivities to VEGF, flt-1, and
flk-1 were observed in tumour cells, especially in invasive tumour
lesions. Furthermore, the intensity of immunostaining for VEGF
was very closely correlated with that of flk-1. Similar finding was
also reported by Takahashi et al (1995). They observed that most
tumours with high levels of VEGF were associated with flk-1
positivity in their endothelial cells, indicating that VEGF can up-
regulate its own receptor.
An important question to consider was whether the immuno-
reactivities for all antibodies were specific, or whether the positive
reactivities for the antibodies were false positive. To answer this
question, adult rat brain tissue was chosen as the negative control
for all antibodies as it is well established that adult brain does not
have detectable levels of VEGF and its receptors. Negative reac-
tivity was observed in all negative control sections, whereas the
positive reactivities for VEGF, flt-1 and flk-1 were observed in
fetal rat kidney, a tissue known to contain VEGF. On the other
hand, preincubation of antisera with 50-fold excess of the corre-
sponding antigens (in concentration) all gave a negative result in
1340 B Xie et al
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Figure 17 Western blot analyses of flk-1 (A) and flt-1 (B). Proteins were
extracted from normal mammary gland tissue from untreated control rats and
mammary tumours induced by combination of testosterone and 17b-
oestradiol (1E2+4T). Equal amounts of proteins (100 mg lane–1) were loaded
into the gel and membranes were probed with the rabbit anti-flk-1 antibody
(A) or the rabbit anti-flt-1 antibody (B). The molecular weight standards, as
indicated on the right in each blot are 170 kDa (A and B). The lanes 1, in
both A and B, represent extracts from normal mammary gland tissues. The
lanes 2–4 are extracts from individual mammary tumours, and the lanes 5 in
both A and B are the tumour extracts from lanes 2 in A and B respectively, in
which the primary antibodies, anti-flk-1 or anti-flt-1, were preincubated with
their respective blocking peptides. In A, the flk-1 protein (~170–175 kDa) is
highly expressed in mammary tumours (lanes 2–4) but is very weakly
expressed in normal mammary gland (lane 1). This band is abolished in the
blot preincubated with anti-flk-1 antibody and flk-1 peptide (lane 5). In B, the
overall expression of flt-1 protein (~165–170 kDa) in mammary tumours
(lanes 2–4) is high relative to the normal control (lane 1) but its expression
varied among different tumour samples. This band is attenuated by
preincubation with anti-flt-1 antibody and flt-1 peptideaddition to omission of primary antisera. These results provided
further evidence for the specificity of the immunostaining in our
study.
Western blot experiments demonstrated an increase in flk-1
protein expression in induced mammary cancers. The molecular
size of flk-1 is about 170–175 kDa, which is consistent with other
researcher’s reports (Yamane et al, 1994; Seetharam et al, 1995;
Yang and Cepko, 1996; Takahashi and Shibuya, 1997).
Angiogenesis is essential for development of tumours, including
breast cancer, because angiogenesis supplies not only nutrients
(especially the paracrine stimulators, such as numerous growth
factors, for tumour cells) and oxygen requirements for the growing
tumour but also provide vascular route for metastasis. Therefore,
angiogenesis is a significant prognostic indicator for breast cancer
(Hanahan et al, 1996). Among all factors, VEGF is one of the most
potent inducer of angiogenesis (Hanahan et al, 1996). It is substan-
tially overexpressed in many transformed cell lines and in malig-
nant tumours (Gitay-Goren et al, 1993; Shibuya, 1995; Enomoto et
al, 1994), which are closely correlated with the poor prognosis of
many malignant tumours (Tio et al, 1994). To date, VEGF is
known to be a specific growth factor for endothelial cells because
it has been reported that VEGF receptors, flt-1 and flk-1, are
exclusively present in endothelium (Dvorak et al, 1995; Ferrara,
1995). Although some studies have indicated that receptors are
also expressed by several non-endothelial cells, the binding of
VEGF to the receptors on these cells does not seem to induce cell
proliferation. Rather, it has been noted that VEGF induces motility
of monocytes, differentiation of osteoblasts, production of insulin
by beta cells, and disorganization of actin stress fibres in Balb/c
3T3 cells (Enomoto et al, 1994). These suggest that VEGF is a
multifunctional growth factor in different type of cells. On the
other hand, some researchers have observed the correlation
between expression of VEGF and proliferation of tumour cells.
However, they ascribe the increase of proliferative index to the
angiogenic activity of VEGF because the receptors for VEGF are
restricted to endothelial cells rather than on tumour cells
(Takahashi et al, 1995). Taken together, most studies to date have
been concerned with the effects of VEGF on angiogenic activity.
The observation of receptors in the mammary cancer cells
which overexpress VEGF led us to hypothesize that a VEGF
autocrine loop may exist in mammary cancer (as illustrated in
Figure 18). To verify this hypothesis, we employed a double-
labelling immunostaining approach to determine whether prolifer-
ation of mammary cancer cells was correlated with the expression
of VEGF, flt-1 and flk-1. We resorted to using Ki-67 as a prolifer-
ation marker because Ki-67 was considered to be the best for use
on conventional sections (Rose et al, 1994). Using Ki-67 LI as a
parameter we evaluated the proliferation of mammary cancer cells.
Unlike the relative long half-life of proliferating cell nuclear
antigen (PCNA), which affects the accuracy of scoring, the Ki-67
protein has very short half-life of only approximately 20 min
within the cycle. It is almost totally catabolized at the completion
of mitosis, thus, only very few cells that have left the cycle would
contain this antigen (Ross et al, 1995). Ki-67 has thus been applied
to investigate the growth fractions and cytokinetic activities in
mammary cancer. It has been shown that Ki-67 gives a rapid and
reliable estimate of the neoplastic cell growth fractions (Gerdes et
al, 1986). Moreover, in a retrospective study, Wintzer et al (1991)
have reported that the growth fraction measured by Ki-67 was
found to correlate directly with the T stage, nodal status and
tumour grading. In our study, Ki-67 LI was significantly higher in
cells with strong reactivities to VEGF than those with weak reac-
tivities. This indicates a correlation between expression of Ki-67
and VEGF. This means that tumour cells that express high VEGF
have a higher proliferation rate. Similar correlation was also
observed between Ki-67 and flk-1, but not with flt-1. These data
provide evidence to support our hypothesis that VEGF may be an
autocrine growth factor for mammary cancer cells and that the
autocrine growth regulatory role may be mediated through flk-1.
Although flt-1 is also known to be a receptor for VEGF, recent
experiments have demonstrated that flt-1 do not mediate a clas-
sical proliferative signal (Waltenberger et al, 1994). Our results
support these observations since the expression of flt-1 seems to be
inversely correlated with high Ki-67 LI. Fong et al (1995) have
reported that targeted deletion of the flt-1 gene resulted in
abnormal blood vessel development and early embryonic lethality.
They pointed out that VEGF binding to flt-1 elicits endothelial
cell–cell interactions and capillary tube formation, a process that
follows closely the proliferation and migration of endothelial cells.
Others have reported that flt-1 may play a role in the process of
endothelial reorganization (Millauer et al, 1993). These observa-
tions suggested that flt-1 may be related to the migration of
endothelial cells. In our study, we have observed that flt-1 was
expressed mainly in invasive mammary cancer cells and that flt-1
is inversely correlated to Ki-67 index. These results lead us to
speculate that expression of flt-1 may be responsible for the inva-
sive growth and metastasis of mammary cancer. Western blot
analysis revealed an increase in flt-1 protein expression in all,
though at variable levels in mammary cancers and the molecular
size of flt-1 is about 170 kDa, which is consistent with other
researcher’s observations (Mitola et al, 1997). This result may
provide preliminary evidence to support our speculation.
However, the precise role of flt-1 in mammary cancer requires
further study.
Furthermore, we have established a cell line from the animal
model and observed that this cell line expressed high levels of
VEGF and its receptors (Xie et al, 1999d). In order to further
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Figure 18 Schematic representation of VEGF and its receptors in
mammary cancer. In normal mammary gland epithelial cells secrete very
small, undetectable amount of VEGF to maintain the growth of blood vessels
(indicated by dotted line arrow). In mammary carcinoma there is not only an
up-regulation of VEGF in cancer cells to induce angiogenesis but also an
overexpression of VEGF receptors, flt-1 (R1) and flk-1 (R2). This indicates
that there is an autocrine signalling pathway for regulating the growth and
metastasis in mammary cancer cells. The thin arrows indicate a paracrine
signalling pathway for angiogenesis, whereas the thick arrow indicates the
autocrine loop for growth and metastatic regulation in mammary cancer cellsconfirm the autocrine growth stimulatory action of VEGF in
mammary cancer cells, we treated the cells with exogenous
synthetic VEGF and observed an apparently increased growth rate
in the treated cells (data not shown). On the other hand, we have
applied the same antibodies to ten human mammary cancer
samples. The results were same as observed in our animal model
(data not shown). Taken together, the in vitro study and investiga-
tion on human tissues provide further evidence to support our
hypothesize that VEGF may act as an autocrine growth regulator.
In summary, in this report we have demonstrated that (i)
mammary cancer cells express high level of VEGF as well as its
receptors (flt-1 and flk-1); (ii) expression of VEGF is quantita-
tively related to proliferation of mammary cancer cells; and (iii)
the proliferation of tumour cells is quantitatively correlated to the
expression of flk-1, but not to flt-1. Our findings reveal that VEGF
may act as an autocrine growth factor for mammary cancer cells in
vivo and this autocrine regulatory role may be mediated by flk-1.
The current study has, therefore, shed a new light on the mecha-
nism of mammary carcinogenesis.
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